1BELHABRI A, THOMAS X, WATTEL E, et al. All trans retinoic acid in combination with intermediate-dose cytarabine and idarubicin in patients with relapsed or refractory non promyelocytic acute myeloid leukemia: a phase Ⅱ randomized trial[J]. Hematol J, 2002,3(1): 49-55. 被引量：1
2GANDHI V, ESTEY E, KEATING M J, et al. Fludarabine potentiates metabolism of cytarabine in patients with acute myelogenous leukemia during therapy[J]. J Clin Oncol,1993,11(1):116-124. 被引量：1
4JACKSON G H. Use of fludarabine in the treatment of acute myeloid leukemia[J]. Hematol J, 2004, 5 (Suppl 1):62-67. 被引量：1
5张之南主编..血液病诊断及疗效标准 第2版[M].北京:科学出版社,1998:434.
二级参考文献12
1[1]Belhabri A, Thomas X, Wattel E, et al. All trans retinoic acid in combination with intermediate-dose cytarabine and idarubicin in patients with relapsed or refractory non promyelocytic acute myeloid leukemia: a phase Ⅱ randomized trial [J] . Hematol J,2002,3(1):49 -55. 被引量：1
2[2]Carella AM, Carlier P, Pungolino E, et al. Idarubicin in combination with intermediate -dose cytarabine and VP-16 in the treatment of refractory or rapidly relapsed patients with acute myeloid leukemia. The GIMEMA Cooperative Group [J] .Leukemia, 1993, 7 (2): 196 - 199. 被引量：1
3[3]Ozkaynak MF, Avramis Ⅵ, Carcich S, et al. Pharmacology of cytarabine given as a continuous infusion followed by mitoxantrone with and without amsacrine/etoposide as reinduction chemotherapy for relapsed or refractory pediatric acute myeloid leukemia [J].Med Pediatr Oncol, 1998, 31 (6): 475 -482. 被引量：1
4[4]Harousseau JL, Milpied N, Briere J, et al. Mitoxantrone and intermediate -dose cytarabine in relapsed or refractory acute myeloblastic leukemia [J]. Nouv Rev Fr Hematol, 1990, 32(4):227 - 230. 被引量：1
5[5]Weiss L, Abdul-Hai A, Or R, et al. Fludarabine in combination with cyclophosphamide decreases incidence of GVHD and maintains effective graft-versus-leukemia effect after allogeneic stem cell transplantation in murine lymphocytic leukemia [J].Bone Marrow Transplant, 2003, 31 ( 1 ): 11 - 15. 被引量：1
6[6]McCarthy AJ, Pitcher LA, Hann IM, et al. FLAG(fludarabine,high-dose cytarabine, and G-CSF) for refractory and high-risk relapsed acute leukemia in children [J]. Med Pediatr Oncol, 1999,32(6):411 -415. 被引量：1
7[7]Montillo M, Mirto S, Petti MC, et al. Fludarabine, cytarabine, and G-CSF (FLAG) for the treatment of poor risk acute myeloid leukemia [J]. Am J Hematol, 1998, 58(2): 105 - 109. 被引量：1
8[8]Ferrara F, Palmieri S, Pocali B, et al. De novo acute myeloid leukemia with multilineage dysplasia: treatment results and prognostic evaluation from a series of 44 patients treated with fludarabine, cytarabine and G-CSF (FLAG) [J]. Eur J Haematol,2002, 68(4): 203 - 209. 被引量：1
9[9]Hanel M, Friedrichsen K, Hanel A, et al. Mito-flag as salvage therapy for relapsed and refractory acute myeloid leukemia [J].Onkologie, 2001, 24(4): 356 - 360. 被引量：1
10[10]Jackson G, Taylor P, Smith GM, et al. A multicentre, open,non-comparative phase Ⅱ study of a combination of fludarabine phosphate, cytarabine and granulocyte colony-stimulating factor in relapsed and refractory acute myeloid leukaemia and de novo refractory anaemia with excess of blasts in transformation [J]. Br J Haematol, 2001, 112(1): 127 - 137. 被引量：1
